TERN 101

Drug Profile

TERN 101

Alternative Names: TERN-101

Latest Information Update: 10 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Eli Lilly
  • Developer Terns Pharmaceuticals
  • Class Hepatoprotectants; Small molecules
  • Mechanism of Action Farnesoid X-activated receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Non-alcoholic steatohepatitis

Most Recent Events

  • 04 Apr 2018 TERN 101 licensed to Terns Pharmaceuticals worldwide for the treatment of Non-alcoholic steatohepatitis
  • 04 Apr 2018 Phase-I clinical trials in Non-alcoholic steatohepatitis in European Union, prior to April 2018
  • 04 Apr 2018 Preclinical trials in Non-alcoholic steatohepatitis in China, prior to April 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top